NPM1 and acute myeloid leukemia: Furthermore, to test whether ECHDC3 would be a useful biomarker in re-stratification of AML patients, subgroup analysis was carried out in fav-, int-, and adv-risk AML, as well as in patients with or without NPM1/FLT3 mutation.